Hyperactive striatal neurons in symptomatic Huntington R6/2 mice: Variations with behavioral state and repeated ascorbate treatment

Membrane and morphological abnormalities occur in the striatum of R6/2 transgenics, a widely used mouse model of Huntington's disease. To assess changes in behavior-related neuronal activity, we implanted micro-wire bundles in the striatum of symptomatic R6/2 mice and wild-type controls. Unit activity was recorded in an open-field arena once weekly for the next several weeks. For each recording session, firing rate was monitored before, during, and after a period of light anesthesia to assess the influence of behavioral arousal. Because low ascorbate in striatal extracellular fluid may contribute to Huntington's disease symptoms, all animals received an injection of either 300 mg/kg sodium ascorbate or vehicle for three consecutive days prior to each recording session. In R6/2 mice, regardless of treatment, striatal unit activity was significantly faster than in wild-type controls. The difference in mean (+/-S.E.M.) firing was most apparent during wakefulness (6.4+/-0.8 vs. 3.5+/-0.3 spikes/s) but also persisted during anesthesia (2.0+/-0.3 vs. 0.7+/-0.1 spikes/s). Assessment of treatment duration indicated that R6/2 mean waking discharge rate was significantly slower after three weeks than after one week of ascorbate treatment (3.1+/-0.6 vs. 10.2+/-2.7 spikes/s). Vehicle-treated R6/2s showed no such decline in striatal activity ruling out an age- or injection-related effect. Slow-scan voltammetry in separate animals confirmed that ascorbate-injections returned the level of striatal extracellular ascorbate in R6/2 mice to that of wild-type controls. Our results indicate that although striatal neurons modulate firing in relation to behavioral state, impulse activity is consistently elevated in transgenic relative to wild-type mice. Restoring extracellular ascorbate to the wild-type level reverses this effect suggesting a role for ascorbate in normalizing neuronal function in Huntington's disease striatum.

[1]  P. Mecocci,et al.  Oxidative damage to mitochondrial DNA in Huntington's disease parietal cortex , 1999, Neuroscience Letters.

[2]  M. H. Joseph.  Monitoring neurotransmitter release during behaviour , 1986 .

[3]  S. Tabrizi,et al.  Biochemical abnormalities and excitotoxicity in Huntington's disease brain , 1999, Annals of neurology.

[4]  C. Schwarz,et al.  Wild-Type and Mutant Huntingtins Function in Vesicle Trafficking in the Secretory and Endocytic Pathways , 1998, Experimental Neurology.

[5]  O. Hikosaka.  Role of Basal Ganglia in Control of Innate Movements, Learned Behavior and Cognition—A Hypothesis , 1994 .

[6]  F. Gonon,et al.  Electrochemical treatment of pyrolytic carbon fiber electrodes , 1981 .

[7]  J. Penney,et al.  Differential loss of striatal projection systems in Huntington’s disease: a quantitative immunohistochemical study , 2004, Journal of Chemical Neuroanatomy.

[8]  R. Grünewald.  Ascorbic acid in the brain , 1993, Brain Research Reviews.

[9]  G. Rebec,et al.  Behavioral Activation in Rats Requires Endogenous Ascorbate Release in Striatum , 2001, The Journal of Neuroscience.

[10]  M. Majewska,et al.  Ascorbic acid protects neurons from injury induced by glutamate and NMDA. , 1990, Neuroreport.

[11]  M. Beal,et al.  Mitochondrial dysfunction in neurodegenerative diseases. , 1998, Biochimica et biophysica acta.

[12]  R. Carraway,et al.  Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons , 1995, Neuron.

[13]  J. B. Martin,et al.  Clinical and neuropathologic assessment of severity in Huntington's disease , 1988, Neurology.

[14]  Thomas H Gillingwater,et al.  Progressive abnormalities in skeletal muscle and neuromuscular junctions of transgenic mice expressing the Huntington's disease mutation , 2004, The European journal of neuroscience.

[15]  W. Hauber.  Involvement of basal ganglia transmitter systems in movement initiation , 1998, Progress in Neurobiology.

[16]  K. Maiese,et al.  Oxidative stress in the brain: Novel cellular targets that govern survival during neurodegenerative disease , 2005, Progress in Neurobiology.

[17]  P. Calabresi,et al.  Metabotropic Glutamate Receptors and Cell-Type-Specific Vulnerability in the Striatum: Implication for Ischemia and Huntington's Disease , 1999, Experimental Neurology.

[18]  C. Cepeda,et al.  NMDA receptor function in mouse models of Huntington disease , 2001, Journal of neuroscience research.

[19]  M. Fillenz,et al.  Release of ascorbate from a synaptosomal fraction of rat brain , 1984, Neurochemistry International.

[20]  G. Rebec,et al.  Ascorbate modulates glutamate-induced excitations of striatal neurons , 1998, Brain Research.

[21]  M. Fillenz,et al.  The origin of circadian and amphetamine-induced changes in the extracellular concentration of brain ascorbate , 1983, Neurochemistry International.

[22]  P. Groves.  A theory of the functional organization of the neostriatum and the neostriatal control of voluntary movement , 1983, Brain Research Reviews.

[23]  A. Mahal,et al.  Impaired Glutamate Uptake in the R6 Huntington's Disease Transgenic Mice , 2001, Neurobiology of Disease.

[24]  Stephen B. Dunnett,et al.  Characterization of Progressive Motor Deficits in Mice Transgenic for the Human Huntington’s Disease Mutation , 1999, The Journal of Neuroscience.

[25]  W. T. Thach,et al.  Basal ganglia intrinsic circuits and their role in behavior , 1993, Current Opinion in Neurobiology.

[26]  M. Chesselet,et al.  Electrophysiological and morphological changes in striatal spiny neurons in R6/2 Huntington's disease transgenic mice. , 2001, Journal of neurophysiology.

[27]  George Paxinos,et al.  The Mouse Brain in Stereotaxic Coordinates , 2001 .

[28]  C. Cepeda,et al.  Changes in Cortical and Striatal Neurons Predict Behavioral and Electrophysiological Abnormalities in a Transgenic Murine Model of Huntington's Disease , 2001, The Journal of Neuroscience.

[29]  G. Rebec,et al.  Dysregulation of Ascorbate Release in the Striatum of Behaving Mice Expressing the Huntington's Disease Gene , 2002, The Journal of Neuroscience.

[30]  J. Penney,et al.  The functional anatomy of basal ganglia disorders , 1989, Trends in Neurosciences.

[31]  G. Rebec,et al.  A vitamin as neuromodulator: Ascorbate release into the extracellular fluid of the brain regulates dopaminergic and glutamatergic transmission , 1994, Progress in Neurobiology.

[32]  L. Wollmuth,et al.  Structure and gating of the glutamate receptor ion channel , 2004, Trends in Neurosciences.

[33]  K. Lindenberg,et al.  Impaired glutamate transport and glutamate-glutamine cycling: downstream effects of the Huntington mutation. , 2002, Brain : a journal of neurology.

[34]  R. Ferrante,et al.  Neuropathological Classification of Huntington's Disease , 1985, Journal of neuropathology and experimental neurology.

[35]  R. Adams,et al.  The pharmacological profile of glutamate-evoked ascorbic acid efflux measured by in vivo electrochemistry , 1991, Brain Research.

[36]  Manish S. Shah,et al.  A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes , 1993, Cell.

[37]  R. Pierce,et al.  Intraneostriatal administration of glutamate antagonists increases behavioral activation and decreases neostriatal ascorbate via nondopaminergic mechanisms , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[38]  Shihua Li,et al.  Cellular Defects and Altered Gene Expression in PC12 Cells Stably Expressing Mutant Huntingtin , 1999, The Journal of Neuroscience.

[39]  A H Schapira,et al.  Mitochondrial dysfunction and free radical damage in the Huntington R6/2 transgenic mouse , 2000, Annals of neurology.

[40]  M. Armstrong‐James,et al.  Modulation of neostriatal activity by iontophoresis of ascorbic acid , 1985, Brain Research.

[41]  M. Fillenz,et al.  Striatal Ascorbate and its Relationship to Dopamine Receptor Stimulation and Motor Activity , 1991, The European journal of neuroscience.

[42]  S. Hersch,et al.  Identification and localization of huntingtin in brain and human lymphoblastoid cell lines with anti-fusion protein antibodies. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[43]  Bertil Hille,et al.  G protein-coupled mechanisms and nervous signaling , 1992, Neuron.

[44]  G. Rebec,et al.  Stimulation of both D1 and D2 dopamine receptors increases behavioral activation and ascorbate release in the neostriatum of freely moving rats. , 1990, European journal of pharmacology.

[45]  M. Chesselet,et al.  Time course of early motor and neuropathological anomalies in a knock‐in mouse model of Huntington's disease with 140 CAG repeats , 2003, The Journal of comparative neurology.

[46]  G. Rebec,et al.  Corticostriatal and thalamic regulation of amphetamine-induced ascorbate release in the neostriatum , 1990, Pharmacology Biochemistry and Behavior.

[47]  S. Lipton,et al.  Molecular pathways to neurodegeneration , 2004, Nature Medicine.

[48]  C. Blakemore,et al.  Dendritic spine pathology and deficits in experience‐dependent dendritic plasticity in R6/1 Huntington's disease transgenic mice , 2004, The European journal of neuroscience.

[49]  M. Fillenz,et al.  Circadian changes in extracellular ascorbate in rat cortex, accumbens, striatum and hippocampus: Correlations with motor activity , 1985, Neuroscience Letters.

[50]  G. Rebec,et al.  Ascorbate treatment attenuates the Huntington behavioral phenotype in mice , 2003, Neuroreport.